Drug Profile
18F GP1
Alternative Names: 18F-GPI; 18F-GP1; F18-GP1; GP1-18F; GP1-F18Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Life Molecular Imaging; University of Zurich
- Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 07 Nov 2019 Asan Medical Center plans a phase II trial for Deep vein thrombosis (Diagnosis) in South Korea (NCT04156230)
- 29 Aug 2019 University of Edinburgh plans a clinical trial for Thrombosis and Aortic valve disorders (Diagnosis) in September 2019 (NCT04073875)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis(Diagnosis) in Switzerland (Parenteral, Injection)